Virdalis — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A Singapore gene therapy firm targeting rare monogenic diseases with viral vectors.

Rare Disease

Proprietary viral vector engineering platform, focusing on AAV capsid optimization and tissue-specific gene delivery for rare genetic disorders.

Orphan drug designations provide regulatory and commercial incentives, and successful therapies can command high value.

Significant risks include potential immunogenicity, long-term durability uncertainties, and complex, costly manufacturing.

Competes in the high-stakes but scientifically challenging rare disease gene therapy sector, where manufacturing and delivery are critical hurdles.